哈佛大学David J. Mooney课题组近日综述了用于肿瘤靶向治疗的聚糖代谢标记的最新研究进展。 该文章于2020年11月20日发表于《自然—化学》。

非天然糖类既可以通过理性设计使其选择性地标记癌细胞，也可以使其特异性地递送至肿瘤组织中。在这篇综述文章中，作者讨论了到目前为止设计和递送用于癌细胞代谢标记的非天然糖以及后续的肿瘤靶向治疗的研究进展。作者还讨论了用于肿瘤免疫治疗的细胞代谢标记。最后，作者还展望了用于开发可临床转化的强效抗肿瘤疗法的癌细胞与免疫细胞的代谢标记的未来研究方向。

据了解，利用非天然糖进行糖代谢工程是在细胞膜上标记化学标签的一种强有力的工具，这些化学标签可通过高效的化学反应与其他分子“货物”偶合，实现后续的靶向递送。这项技术已被广泛用于癌症标记和靶向治疗。然而，由于这种代谢标记可发生在肿瘤细胞或正常细胞中，为了开发肿瘤靶向疗法，必须要实现肿瘤的选择性标记。

附：英文原文

Title: Metabolic glycan labelling for cancer-targeted therapy

Author: Hua Wang, David J. Mooney

Issue&Volume: 2020-11-20

Abstract: Metabolic glycoengineering with unnatural sugars provides a powerful tool to label cell membranes with chemical tags for subsequent targeted conjugation of molecular cargos via efficient chemistries. This technology has been widely explored for cancer labelling and targeting. However, as this metabolic labelling process can occur in both cancerous and normal cells, cancer-selective labelling needs to be achieved to develop cancer-targeted therapies. Unnatural sugars can be either rationally designed to enable preferential labelling of cancer cells, or specifically delivered to cancerous tissues. In this Review Article, we will discuss the progress to date in design and delivery of unnatural sugars for metabolic labelling of tumour cells and subsequent development of tumour-targeted therapy. Metabolic cell labelling for cancer immunotherapy will also be discussed. Finally, we will provide a perspective on future directions of metabolic labelling of cancer and immune cells for the development of potent, clinically translatable cancer therapies.

DOI: 10.1038/s41557-020-00587-w

Source: https://www.nature.com/articles/s41557-020-00587-w